Per 0.5 mL Purified Bordetella pertussis antigens: Recombinant pertussis toxin (PTgen) 5 mcg, filamentous haemagglutinin (FHA) 5 mcg
Indications/Uses
Active booster immunization against pertussis in individuals ≥3 yr. Passive protection against pertussis in early infancy following maternal immunization during pregnancy.
View Pertagen overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity to purified Bordetella pertussis antigens or formaldehyde. History or signs of severe allergic reaction or any encephalopathy w/ unknown origin following administration of pertussis vaccines or to any components of vaccine; neurological disorders, uncontrolled epilepsy or progressive encephalopathy.
Appropriate medical care should be readily available in case of rare anaphylactic reaction after vaccination. Not to be administered IV. Postpone vaccination in patients suffering from acute severe febrile illness. Syncope (fainting). Immunosuppressed patients. Patients who experienced high fever (≥40°C) w/in 48 hr after immunization w/ any pertussis vaccines w/o any identifiable causes; receiving anticoagulant therapy or those w/ thrombocytopenia or any coagulation disorder. Review medical history prior to vaccination. Administer at different inj site if to be given concomitantly w/ other vaccines or Ig.